REGN
Price
$819.09
Change
+$13.42 (+1.67%)
Updated
Oct 22 closing price
Capitalization
84.33B
7 days until earnings call
Intraday BUY SELL Signals
RPRX
Price
$63.75
Change
+$1.60 (+2.57%)
Updated
Oct 22 closing price
Capitalization
28.39B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REGN vs RPRX

REGN vs RPRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REGN vs. RPRX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and RPRX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for REGN with price predictions
Oct 22, 2026

REGN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for REGN turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 55 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 43%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.659) is normal, around the industry mean (2.973). P/E Ratio (19.563) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (128.121) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for RPRX with price predictions
Oct 22, 2026

RPRX in upward trend: price rose above 50-day moving average on October 15, 2026

RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 49 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 59%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 50 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.

The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 29 of 52 cases over the following month. The odds of a continued upward trend are 56%.

The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.

Following a +3.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 176 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RPRX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.154) is normal, around the industry mean (2.973). P/E Ratio (34.091) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.015) settles around the average of (128.121) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
REGN vs RPRX: Fundamental Ratings
REGN
RPRX
OUTLOOK RATING
1..100
1627
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
8123
SMR RATING
1..100
5997
PRICE GROWTH RATING
1..100
1939
P/E GROWTH RATING
1..100
154
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (89) in the Biotechnology industry is in the same range as RPRX (92) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's Profit vs Risk Rating (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (81) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that REGN’s stock grew somewhat faster than RPRX’s over the last 12 months.

REGN's Price Growth Rating (19) in the Biotechnology industry is in the same range as RPRX (39) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as REGN (15) in the Biotechnology industry. This means that RPRX’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNRPRX
RSI
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
56%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
57%
MACD
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
56%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
59%
Advances
ODDS (%)
Bullish Trend 8 days ago
65%
Bullish Trend 7 days ago
56%
Declines
ODDS (%)
Bearish Trend 4 days ago
56%
Bearish Trend 17 days ago
49%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
51%
Aroon
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
70%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (REGN: $819.09 vs. RPRX: $63.75)
Brand notoriety: REGN: Notable vs. RPRX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 140% vs. RPRX: 95%
Market capitalization -- REGN: $84.33B vs. RPRX: $28.39B
REGN [@Biotechnology] is valued at $84.33B. RPRX’s [@Biotechnology] market capitalization is $28.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 2 FA rating(s) are green while RPRX’s FA Score has 2 green FA rating(s).

  • REGN’s FA Score: 2 green, 3 red.
  • RPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, RPRX is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 5 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s).

  • REGN’s TA Score: 5 bullish, 5 bearish.
  • RPRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both REGN and RPRX are a good buy in the short-term.

Price Growth

REGN (@Biotechnology) experienced а +2.86% price change this week, while RPRX (@Biotechnology) price change was +6.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

REGN is expected to report earnings on Oct 30, 2026.

RPRX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
REGN
Daily Signal:
Gain/Loss:
RPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+1.67%
VRTX - REGN
43%
Loosely correlated
+2.03%
RPRX - REGN
37%
Loosely correlated
+2.57%
BMRN - REGN
36%
Loosely correlated
+2.57%
ARQT - REGN
36%
Loosely correlated
+1.04%
INCY - REGN
34%
Loosely correlated
+3.08%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+2.57%
AXON - RPRX
48%
Loosely correlated
+2.98%
INCY - RPRX
46%
Loosely correlated
+3.08%
VRTX - RPRX
46%
Loosely correlated
+2.03%
RIGL - RPRX
39%
Loosely correlated
-0.04%
EXEL - RPRX
38%
Loosely correlated
+1.13%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GMRS10.770.37
+3.56%
GMR Solutions Inc
REZI17.790.31
+1.77%
Resideo Technologies
AIZ288.854.55
+1.60%
Assurant
FUSB16.590.16
+0.97%
First US Bancshares
CWD0.40N/A
+0.40%
CaliberCos Inc